Manufacturing

The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.

The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.

The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.

The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.

Integration of Brooks Life Sciences BioStore III automated storage and inventory monitoring solution with Cytiva’s Chronicle software will improve traceability, process control, and monitoring capabilities.

Rentschler Biopharma will establish its manufacturing capability for advanced therapy medicinal products at the CGT Catapult site in Stevenage, UK.

Evonik has revealed plans for investment in the short-term expansion of its specialty lipids production, which are used with mRNA-based COVID-19 vaccines.

The companies will build capacity in Germany that will be ready in 2022 and are exploring options for increasing volume in 2021.

How can artificial intelligence and machine learning be used to gather and process real-time manufacturing data?

Lessons learned from the pandemic can advance future biologic drug development and manufacturing.

The company recently installed a fully validated visual inspection system that uses artificial intelligence in an automated inspection machine.

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

As demand for COVID-19 vaccines increases, Big Pharma offers its manufacturing capacity and expertise.

A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis

WuXi STA will acquire the site’s operations and assets, including the plant, equipment, and workforce.

Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.

Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.

Connected, integrated bioprocessing enterprises with greater data analytics capabilities are coming.

A unified scale-up approach, as presented here, can be applied to any unit operation.

CDMOs address the unique challenges of liquid and lyophilized forms as well as preparing for the large capacity needed for COVID-19 vaccines.

A complicated vaccination rollout and mixed messages may derail the pandemic endgame

Cytiva acquired Vanrx Pharmasystems, a Canadian manufacturer of robotic aseptic filling equipment.

Biotechnology company, Polyplus-transfection, has started construction of a new facility in France to meet growth in the cell and gene therapy market.

The dispute between the European Commission (EC) of the European Union and pharmaceutical company AstraZeneca continues.

The launch of HiScreen Fibro PrismA, the company’s newest product for early mAb purification process development strengthens Cytiva’s new fiber-based Protein A platform.

Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.

Sanofi will offer access to its infrastructure and expertise to help BioNTech produce over 125 million doses of its COVID-19 vaccine in Europe.

Clinical material for a Theratechnologies product in development will be produced at PPS’ manufacturing facility in Lexington, KY.

The 40,000-ft.2 facility will feature eight cleanrooms with configurations for the production of cell and viral vector products.

Henogen will be integrated into Thermo Fisher’s Pharma Services business within its Laboratory Products and Services segment.